Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

STAT3 inhibitor BBI608 enhances the antitumor effect of gefitinib on EGFR-mutated non-small cell lung cancer cells.

Human cell - 1 Nov 2021

Wang Qian, Lu Bing, Zhang Yi, Yu Jing, Guo Jie, Zhou Qianchi, Lv Hong, Sun Yifeng

Abstract excerpt

Gefitinib is known as epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) while an increasing number of patients with non-small cell lung cancer (NSCLC) are becoming resistant to EGFR-TKI. Therefore, innovative methods are urgently needed to overcome primary and acquired resistance to EGFR-TKIs in NSCLC patients. The viability of HCC827 cells and HCC827 Ge-resistant (Ge-r) cells treated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Apoptosis
Share to Cell Movement

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Gene Expression

Share to Gene Expression Regulation, Neoplastic

Share to Lung Neoplasms

Share to Mutation

Source

Identifiers

PMID: 34370268
DOI: 10.1007/s13577-021-00582-4

Genes

STAT3
ROR1
EGFR
ABCB1
CCK
MMP2
MMP9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

STAT3 inhibitor BBI608 enhances the antitumor effect of gefitinib on EGFR-mutated non-small cell lung cancer cells.PMID 34370268Read ↗

Combination of Huanglian Jiedu Decoction and erlotinib delays growth and improves sensitivity of EGFR‑mutated NSCLC cells in vitro and in vivo via STAT3/Bcl‑2 signaling.Semantic proximity Read ↗

MiR-618 suppresses the proliferation, invasion, and migration of non-small lung cancer via the JAK2/STAT3 axisSemantic proximity Read ↗

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.Semantic proximity Read ↗

The miR‑625‑3p/AXL axis induces non‑T790M acquired resistance to EGFR‑TKI via activation of the TGF‑β/Smad pathway and EMT in EGFR‑mutant non‑small cell lung cancer.Semantic proximity Read ↗

MiR‐133a‐3p attenuates resistance of non‐small cell lung cancer cells to gefitinib by targeting SPAG5Semantic proximity Read ↗

Tyrosine kinase inhibitor-induced IL-6/STAT3 activation decreases sensitivity of EGFR-mutant non-small cell lung cancer to icotinib.Semantic proximity Read ↗

Inhibition of non-small cell lung cancer (NSCLC) growth by a novel small molecular inhibitor of EGFR.Semantic proximity Read ↗

A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R.Semantic proximity Read ↗

MiRNA-153-3p promotes gefitinib-sensitivity in non-small cell lung cancer by inhibiting ATG5 expression and autophagy.Semantic proximity Read ↗

Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway.Semantic proximity Read ↗

Effect of almonertinib on the proliferation, invasion, and migration in non-small cell lung cancer cells.Semantic proximity Read ↗

Zoledronic acid increases the antitumor effect of gefitinib treatment for non-small cell lung cancer with EGFR mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.